
The study evaluated the cost-effectiveness of faricimab as a first-line treatment for neovascular age-related macular degeneration (nAMD) compared to bevacizumab using data from the Swedish Macula Registry (2017-2022). The analysis found that faricimab resulted in an incremental societal cost of 277 EUR per patient, driven by higher medication costs (1516 EUR), while visit costs (−1183 EUR) and patient travel costs (−56 EUR) were lower due to extended injection intervals. Faricimab was similarly cost-effective for patients living farther from clinics. These results suggest that faricimab is a cost-effective alternative, particularly beneficial for optimizing treatment intervals and healthcare resources.
Like
Save
Share